Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of recurrent ischemic stroke after non-cardioembolic ischemic stroke in England and Denmark.

Journal of neurology·2026
Same author

Tsunamis hiding in plain sight: spreading depression in clinical neurology.

Nature reviews. Neurology·2026
Same author

Triptans for Migraine: Balancing Potential Vascular Risk With Meaningful Benefit.

Journal of the American Heart Association·2026
Same author

Pre-hospital treatment duration and efficacy of remote ischaemic conditioning in the RESIST randomised-controlled trial.

European stroke journal·2026
Same author

Rates and risk factors for major adverse cardiovascular and cerebrovascular events after stroke due to intracerebral hemorrhage: Systematic review and study-level meta-analysis.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

2025 Highlights in central and peripheral interactions in migraine.

Cephalalgia : an international journal of headache·2026

Related Experiment Video

Updated: Jul 4, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K

Risk of Stroke and Myocardial Infarction Among Initiators of Triptans.

Christian Lund Petersen1,2, Anders Hougaard3,4, David Gaist5

  • 1Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.

JAMA Neurology
|February 5, 2024
PubMed
Summary

Triptan use may increase the risk of ischemic stroke and myocardial infarction, particularly in high-risk patients. However, the absolute risk for individuals with low cardiovascular risk remains very low.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K

Related Experiment Videos

Last Updated: Jul 4, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

14.9K

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Triptans are often contraindicated in patients with ischemic heart disease due to potential cardiovascular risks.
  • Previous observational studies have yielded conflicting results regarding the association between triptan use and ischemic events.
  • The clinical significance of avoiding triptan treatment in patients with cardiovascular risk factors remains unclear.

Purpose of the Study:

  • To investigate the association between triptan initiation and ischemic events using a robust self-controlled study design.
  • To mitigate confounding factors inherent in traditional observational studies.

Main Methods:

  • A nationwide case-crossover study was conducted using Danish registries from January 1995 to August 2022.
  • Individuals initiating triptans and experiencing ischemic outcomes (myocardial infarction, ischemic stroke) were identified.
  • Triptan exposure in the 2 weeks preceding an event was compared to four 2-week reference periods.

Main Results:

  • The study included 429,612 individuals initiating triptans.
  • Triptan initiation was associated with an increased risk of myocardial infarction (OR, 3.3) and ischemic stroke (OR, 3.2).
  • Patients experiencing events were older and had a higher cardiovascular risk profile.

Conclusions:

  • Triptan initiation appears to be associated with an elevated risk of ischemic stroke and myocardial infarction.
  • The absolute risk of ischemic events following triptan initiation is very low for individuals with low baseline cardiovascular risk.
  • These findings highlight the importance of individualized risk assessment when prescribing triptans.